These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38309725)

  • 1. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.
    Esposito Abate R; Pasquale R; Sacco A; Simeon V; Maiello MR; Frezzetti D; Chiodini P; Normanno N
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB
    Ramos-Paradas J; Hernández-Prieto S; Lora D; Sanchez E; Rosado A; Caniego-Casas T; Carrizo N; Enguita AB; Muñoz-Jimenez MT; Rodriguez B; Perez-Gonzalez U; Gómez-Sánchez D; Ferrer I; Ponce Aix S; Nuñez Buiza Á; Garrido P; Palacios J; Lopez-Rios F; Garrido-Martin EM; Paz-Ares L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.
    Choi SJ; Lee JB; Kim JH; Hong MH; Cho BC; Lim SM
    Ther Adv Med Oncol; 2024; 16():17588359241240657. PubMed ID: 38523846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.
    Wei B; Kang J; Kibukawa M; Arreaza G; Maguire M; Chen L; Qiu P; Lang L; Aurora-Garg D; Cristescu R; Levitan D
    J Mol Diagn; 2022 Jun; 24(6):600-608. PubMed ID: 35218944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.
    Esposito Abate R; Cheetham MH; Fairley JA; Pasquale R; Sacco A; Nicola W; Deans ZC; Patton SJ; Normanno N
    Virchows Arch; 2023 Feb; 482(2):347-355. PubMed ID: 36355212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability.
    Heeke S; Benzaquen J; Hofman V; Long-Mira E; Lespinet V; Bordone O; Marquette CH; Delingette H; Ilié M; Hofman P
    J Thorac Oncol; 2020 Sep; 15(9):1535-1540. PubMed ID: 32450274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.
    Huang RSP; Carbone DP; Li G; Schrock A; Graf RP; Zhang L; Murugesan K; Ross JS; Tolba K; Sands J; Oxnard GR; Spigel D
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
    Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
    PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
    Stenzinger A; Endris V; Budczies J; Merkelbach-Bruse S; Kazdal D; Dietmaier W; Pfarr N; Siebolts U; Hummel M; Herold S; Andreas J; Zoche M; Tögel L; Rempel E; Maas J; Merino D; Stewart M; Zaoui K; Schlesner M; Glimm H; Fröhling S; Allen J; Horst D; Baretton G; Wickenhauser C; Tiemann M; Evert M; Moch H; Kirchner T; Büttner R; Schirmacher P; Jung A; Haller F; Weichert W; Dietel M
    J Thorac Oncol; 2020 Jul; 15(7):1177-1189. PubMed ID: 32119917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.
    Jung J; Heo YJ; Park S
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
    Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
    JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
    Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
    J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.
    Bubendorf L; Zoche M; Dafni U; Rüschoff JH; Prince SS; Marti N; Stavrou A; Kammler R; Finn SP; Moch H; Peters S; Stahel RA
    Lung Cancer; 2022 Dec; 174():27-35. PubMed ID: 36283211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
    Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
    J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
    Merino DM; McShane LM; Fabrizio D; Funari V; Chen SJ; White JR; Wenz P; Baden J; Barrett JC; Chaudhary R; Chen L; Chen WS; Cheng JH; Cyanam D; Dickey JS; Gupta V; Hellmann M; Helman E; Li Y; Maas J; Papin A; Patidar R; Quinn KJ; Rizvi N; Tae H; Ward C; Xie M; Zehir A; Zhao C; Dietel M; Stenzinger A; Stewart M; Allen J;
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
    Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.